



## Research Article

# Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis

Liyan Yu,<sup>1</sup> Xuemei Liang,<sup>2</sup> Jianwei Wang,<sup>3</sup> Guangxiang Ding,<sup>3</sup> Jinhai Tang,<sup>3</sup> Juan Xue,<sup>3</sup> Xin He,<sup>2</sup> Jingxuan Ge,<sup>2</sup> Xianzhang Jin,<sup>2</sup> Zhiyi Yang,<sup>2</sup> Xianwei Li,<sup>2</sup> Hehuan Yao,<sup>2</sup> Hongtao Yin,<sup>2</sup> Wu Liu,<sup>2</sup> Shengchen Yin,<sup>2</sup> Bing Sun<sup>ID</sup>,<sup>2</sup> and Junxiu Sheng<sup>ID</sup><sup>3</sup>

<sup>1</sup>Department of Respiratory, The First Affiliated Hospital of Dalian Medical University, Dalian 116044, Liaoning Province, China

<sup>2</sup>Department of Thoracic Surgery, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China

<sup>3</sup>Department of Radiation Oncology, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China

Correspondence should be addressed to Bing Sun; [dysunbing@163.com](mailto:dysunbing@163.com) and Junxiu Sheng; [331780221@qq.com](mailto:331780221@qq.com)

Received 4 October 2022; Revised 4 November 2022; Accepted 18 November 2022; Published 3 January 2023

Academic Editor: Ying Kun Xu

Copyright © 2023 Liyan Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Non-small cell lung cancer (NSCLC) is the most prevalent malignant tumor of the lung cancer, for which the molecular mechanisms remain unknown. In this study, we identified novel biomarkers associated with the pathogenesis of NSCLC aiming to provide new diagnostic and therapeutic approaches for NSCLC by bioinformatics analysis. **Methods.** From the Gene Expression Omnibus database, GSE118370 and GSE10072 microarray datasets were obtained. Identifying the differentially expressed genes (DEGs) between lung adenocarcinoma and normal samples was done. By using bioinformatics tools, a protein-protein interaction (PPI) network was constructed, modules were analyzed, and enrichment analyses were performed. The expression and prognostic values of 14 hub genes were validated by the GEPIA database, and the correlation between hub genes and survival in lung adenocarcinoma was assessed by UALCAN, *cBioPortal*, String and Cytoscape, and Timer tools. **Results.** We found three genes (PIK3R1, SPP1, and PECAM1) that have a clear correlation with OS in the lung adenocarcinoma patient. It has been found that lung adenocarcinoma exhibits high expression of SPP1 and that this has been associated with poor prognosis, while low expression of PECAM1 and PIK3R1 is associated with poor prognosis ( $P < 0.05$ ). We also found that the expression of SPP1 was associated with miR-146a-5p, while the high expression of miR-146a-5p was related to good prognosis ( $P < 0.05$ ). On the contrary, the lower miR-21-5p on upstream of PIK3R1 is associated with a higher surviving rate in cancer patients ( $P < 0.05$ ). Finally, we found that the immune checkpoint genes CD274(PD-L1) and PDCD1LG2(PD-1) were also related to SPP1 in lung adenocarcinoma. **Conclusions.** The results indicated that SPP1 is a cancer promoter (oncogene), while PECAM1 and PIK3R1 are cancer suppressor genes. These genes take part in the regulation of biological activities in lung adenocarcinoma, which provides a basis for improving detection and immunotherapeutic targets for lung adenocarcinoma.

## 1. Introduction

There are 234,030 newly diagnosed lung cancer patients in 2018. Lung cancer is the leading cause of morbidity and mortality among malignant tumors, and the incidence and mortality rate are increasing year by year [1]. There are approximately 85% of lung cancer cases that are non-small cell lung cancer (NSCLC) [2]. It is still difficult to predict the

prognosis for lung cancer despite the progress made in targeted drugs and immunotherapy. It is reported that the 5-year survival rate of NSCLC patients is less than 20%. The main treatments for NSCLC are surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Chemotherapy and targeted drug therapy are the most common and effective treatments for NSCLC, especially for patients with recurrence and metastasis [3–5]. However, chemical

antitumor drugs have great side effects, and patients are poorly tolerated. Targeted drugs combined with chemotherapy can reduce the side effects of chemotherapy, but they are still drug resistant after a period of use [6–8]. The use of molecular diagnosis and treatment has become increasingly important to the treatment of non-small cell lung cancer in recent years [9, 10]. As a result, it is imperative to pinpoint the precise molecular mechanisms of the occurrence, development, invasion, and metastasis of NSCLC. In view of this, the development of new molecular biomarkers is vital for early diagnosis, prevention, and precision treatment.

It is increasingly common to use bioinformatics to identify biomarkers associated with certain diseases. At present, the bioinformatics technology provides a basis for further research on disease pathways and cellular activity networks by exploiting the underlying genetic and molecular mechanisms of disease. In this study, microarray datasets GSE118370 and GSE10072 were obtained from the Integrated Gene Expression Database (GEO) to identify differentially expressed genes (DEGs) between lung adenocarcinoma and adjacent normal tissues consisting of gene expression data for 66 lung adenocarcinoma samples of patients and 55 samples of normal lung tissue. In order to gain a deeper understanding of how these DEGs function biologically, pathway enrichment analysis using the Genomics Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) was conducted. In addition, we created a protein-protein interaction (PPI) network related to DEGs.

With the help of String's online tool, the protein interaction between DEGs was constructed and then beautified with Cytoscape. Then, we searched for the hub gene using the CytoHubba plugin in Cytoscape. For this study, we used four different models to identify the hub genes that were most significant. In the last step, we will use tools such as UALCAN, *cBioPortal*, String, Cytoscape, and Timer to discover the gene and to learn about its role in the biological system. We demonstrated that SPP1 and PIK3R1 were possible biomarkers of lung adenocarcinoma. Further investigation revealed which we were pleasantly surprised to find that both SPP1 and PIK3R1 were associated with lung adenocarcinoma prognoses and immunotherapy. In conclusion, this study aims to develop promising new biomarkers from a new perspective for the diagnosis, prognosis, and molecular target therapy or immunotherapy of NSCLC.

## 2. Methods

**2.1. Data Resources.** The NCBI-GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) [11] contains microarrays, chips, and gene expression data, which is an open high-throughput functional genome database. The microarray data of GSE10072 data (including 58 lung adenocarcinoma samples and 49 normal lung tissue samples) and GSE118370 data (including 6 lung adenocarcinoma samples and 6 normal lung tissue samples) are based on GPL96-57554 and GPL570-55999 platforms from the NCBI-GEO database (Figure 1).

The Limma package in R language was used to identify genes that differ in expression between lung cancer and normal lung tissues [12]. The DEGs were screened using the

R studio's limma package, which performs log<sub>2</sub> conversion and normalization of the matrix data. Through the Affy package, the GSE10072 and GSE118370 raw microarray data were processed in the R studio and standardized by the RMA method. The cutoff criteria were adjusted to  $P < 0.05$ , (logFC) which was  $> 1$  or  $< -1$ . DEGs were visualized using a hierarchical clustering heat map and a volcano map.

We used the GEPIA website (<https://gepia.cancer-pku.cn>) to probe the DEGs of lung adenocarcinoma in TCGA database [13]. In this research, DEGs were defined as  $P$  value  $< 0.05$ , and the (logFC) value was  $> 1$  or  $< -1$ . Then, funrichVenn software was used to integrate the two data sets to obtain the common up-regulated and down-regulated DEGs.

**2.2. GO and Pathway Enrichment Analysis.** The pathway enrichment analysis was performed to determine the biological functions of the overlapping DEGs, based on FUNRICH software. We used the online WebGestalt (<https://www.webgestalt.org/>) tool for GO (Gene Ontology) enrichment, which is an extensively used method to investigate the molecular function (MF), cell component (CC), biological process (BP), and site of expression of genes or gene products for the analysis of DEGs [14]. The KEGG pathway was analyzed by the CLUGO [15] plugin in Cytoscape software (<https://www.cytoscape.org/>) [16]. PANTHER and REACTOME [17, 18] were also widely used databases for systematic analysis of high-level gene functions by KOBAS, using the CLUGO plugin in Cytoscape software. Significant pathways with  $P$  value  $< 0.05$  and the top 20 plotted were visualized by the R language.

**2.3. PPI Network Establishment and Module Analysis.** To better illustrate the existence of potential interactive relationships between overlapping DEGs, we selected the online database search tool String (<https://string-db.org/>) to retrieve interacting genes [19]. The first step is to draw the PPI network diagram for DEGs using the String website. Then, Cytoscape was applied to identify the top 30 genes based on the DEGREE, MCC, DMNC, and MNC methods generated by CytoHubba [20] plugin in Cytoscape software. The top common genes were identified according to the previously mentioned four methods which were selected as hub genes using FUNRICH software.

**2.4. Expression and Survival Analysis of Hub Genes.** To confirm differential expression of hub genes between lung adenocarcinoma and normal lung tissues, we validated each hub gene in TCGA database by using the online tool GEPIA website (<https://gepia.cancer-pku.cn>). Correlation between DEG expression and overall survival (OS) in lung adenocarcinoma was also analyzed using the same tool website on the GEPIA online database.  $P$  value  $< 0.05$  was considered statistically significant.

**2.5. Upstream miRNA Prediction and Survival Analysis.** Upstream miRNA prediction and survival analysis of the three genes (SPP1, PIK3R1, and PECAM1) were conducted with the miRtarbase, and the miRNA survival analysis was




FIGURE 1: Flow chart of data preparation, processing, analysis, and validation.

used by the OncoLnc (<https://www.oncolnc.org/>) [21] website.  $P$  value  $<0.05$  was considered statistically significant.

**2.6. Analysis of the Target Gene.** Based on survival analysis, we analyzed the target gene which was identified from the hub genes using the UALCAN (<https://ualcan.path.uab.edu/index.html>) [22], GEPIA, STRING, and DAVID [23] online websites. In order to get the distribution and relationship of all proteins, we used the Human Protein Atlas (<https://www.proteinatlas.org/>) [24]. The protein expression level of target genes was verified in the Human Protein Atlas.  $P$  value  $<0.05$  was considered statistically significant.

**2.7. mRNA Expression Correlates with Immune Cell Infiltration and Immune Checkpoint Activation.** The TIMER website (<https://cistrome.shinyapps.io/timer/>) [25] focuses on analyzing tumor immune relationships. TIMER was used to analyze mRNA expression data of SPP1 in TCGA database which was correlated with tumor infiltration and immune checkpoints.  $P$  value  $<0.05$ , and the  $(\log FC)$  value was  $>1$  or  $<-1$  was considered statistically significant.

### 3. Results

**3.1. Identification of DEGs in Lung Adenocarcinoma.** In this study, we obtained gene expression profiles from lung carcinoma samples and normal lung tissues from the

GSE10072 and GSE118370 datasets, as well as analyses of DEGs from TCGA database for lung carcinoma samples and normal lung tissues. A hierarchical clustering heat map and a volcano map were created to visualize DEGs (Figures 2(a) and 2(b)). By using *R* studio, we identified 800 and 2092 DEGs from GSE10072 and GSE118370 using the cutoff criterion of  $P=0.05$  and  $(\log FC)>1$ , respectively. Employing Venn analysis by FUNRICH software, we identified 88 up-regulated DEGs and 224 down-regulated DEGs both in GSE10072 and GSE118370 (Figures 2(c) and 2(d)).

**3.2. Pathway Enrichment Analysis.** To initially identify the biological classification of DEGs, we used the GO analysis (three methods: CC, MF, and BP), biological pathway, site of expression pathway, KEGG, PANTHER, and REACTOM through FUNRICH software. A major change of DEGs in CC occurs at the extracellular level, plasma membrane level, integral plasma membrane level, extracellular layer, exosome level, and cell-surface level. The differentiation of DEGs in MF is mainly in cell adhesion activity, and there is no differentiation in protease inhibitor activity. The discrepancy of DEGs in the BP is extraordinarily enriched in cell communication, muscle contraction, and signal transduction (Figures 3(a)–3(c)). Based on the biological pathway, DEGs were enriched to epithelial-mesenchymal




FIGURE 2: Identify DEGs shared between the two databases. (a) The heat map and volcano map of GSE10072. (b) The heat map and volcano map of GSE118370. (c) A Venn diagram used to identify 88 promising up-regulated target genes in lung adenocarcinoma. (d) A Venn diagram is used to identify 224 promising down-regulated target genes in lung adenocarcinoma.

transitions as well as cell-surface interactions in the vessel wall (Figure 3(d)). While using the site of the expression pathway, the DEGs are focusing in cerebrospinal and lung (Figure 3(e)). The enrichment of the DEGs is mostly in complement and coagulation cascades, ECM-receptor interaction, cell adhesion molecules (CAMs), focal adhesion, and so on when using KEGG pathway analysis (Figure 3(f)). PANTHER analysis shows the DEGs are mostly enriched for signaling pathways related to integrin signaling, inflammation mediated by chemokine, chemokine signaling, plasminogen activating cascade, and so on (Figure 3(g)). At last, the DEGs are mostly enriched in extracellular matrix organization, signal transduction, metabolism, and so on when using REACTOME pathway analysis (Figure 3(h)).

**3.3. PPI Construction and Screening for Hub Genes.** Our analysis was based on the STRING online tool and Cytoscape software; we constructed a DEG PPI network containing 94 DEGs with 94 nodes and 224 edges identified, as shown in Figure 4. Further analysis of these genes and pathways, as shown in the PPI network, CPB2, SERPING1, CFD, A2M, PROS1, C7, C5AR1, CLU, and THBD, is in the complement and coagulation cascades pathway. Some genes such as HMMR, VWF, SPP1, CD36, LAMC3, THBS2 SDC1,

and so on are in the ECM-receptor interaction pathway, while some genes are the core status for many pathways across them. For example, PIK3R1 gene has 12 pathways, such as insulin resistance, relaxin signaling pathway, signaling pathway regulating stem cell pluripotency, fluid shear stress and atherosclerosis, AGE-RAGE signaling pathway in diabetic complication, focal adhesion, and so on.

In order to study the protein networks associated with these genes, we created a DEG PPI network based on the STRING online database and Cytoscape (Figure 5(a)). The top 20 genes are identified as the most promising hub genes using CytoHubba plugin in Cytoscape software according to the degree, MNC, closeness, and betweenness methods, respectively (Figures 5(b)–5(e)). The genes are selected from the top most connected genes using Venn analysis, and 14 genes are obtained as hub genes which include CDH1, PECAM1, VWF, SPP1, CDH5, TIMP1, ACE, CAV1, CTGF, A2M, CLU, PIK3R1, EPCAM, and ANGPT1 (Figure 5(f)).

**3.4. Expression of Hub Genes and Survival Analysis.** To validate the distinctive expression of the 14 hub genes we got from prewise analysis between lung adenocarcinoma (LUAD) and normal tissues. As a result of using the GEPIA website to analyze the expression level of each hub gene, we




FIGURE 3: Pathway analysis of DEGs based on FUNRICH software. (a-e) GO analysis of CC, MF, BP, biological pathway, and site of expression. (f-h) Bubble diagram of KEGG, PANTHER, and the REACTOME pathway of lung adenocarcinoma. Significant pathways with *P* value < 0.05 and top 20 were plotted by R language.




FIGURE 4: The results of KEGG and the REACTOME pathway analysis with the CLUGO plugin in Cytoscape software.

discovered that 13 hubs were significantly changed in LUAD (Figure 6). There is no statistical difference in gene TIMP1. The up-regulated genes are CDH1, EPCAM, and SPP1 (Figures 6(a)–6(c)), whereas the down-regulated genes are A2M, ACE, ANGPT1, CAV1, CDH5, CLU, CTGF, PECAM1, PIK3R1, and VWF (Figures 6(d)–6(m)).

We carried out a survival analysis of the hub genes by the GEPIA website to investigate the relevance to the survival with lung adenocarcinoma patients. Three genes (PIK3R1, SPP1, and PECAM1) have a clear correlation with OS in lung adenocarcinoma patients (Figure 7(a)). Among the three genes, SPP1 is highly expressed in lung adenocarcinoma compared with normal lung tissue, but PECAM1 and PIK3R1 have low expression in lung adenocarcinoma compared with normal lung tissue, and the high expression of SPP1 is associated with poor prognosis (Figure 7(d)), while a positive prognosis is associated with high PECAM1 and PIK3R1 expression (Figures 7(b) and 7(c)).

**3.5. Upstream microRNA Prediction and Survival Significance Analysis.** The miRtarbase prediction tool was used to predict upstream miRNAs of three genes (SPP1, PIK3R1, and PECAM1) and found two miRNAs related to the two hub genes; miR-146a-5p is associated with SPP1, while miR-21-5p is associated with PIK3R1. However, we don't find any miRNAs significantly related to PECAM1 (Figures 8(a)–8(c)). Then, we analyzed the survival curves of miRNAs by the OncoLnc website. We found that the higher expression of miR-146a-5p on upstream of SPP1 is associated with

a higher surviving rate in cancer patients (Figure 8(d)). On the contrary, lower miR-21-5p on upstream of PIK3R1 is associated with a higher surviving rate in cancer patients (Figure 8(e)),  $P < 0.05$ .

**3.6. The Biological Role of PIK3R1 in Tumors.** PIK3R1 was identified as one of the target genes prior to survival analysis. Here, we analyzed PIK3R1 through the UALCAN website and found that PIK3R1 was highly expressed in lung adenocarcinoma compared with normal lung tissue (Figure 9(a)). The expression of PIK3R1 in different tumors and normal tissues by PAN cancer analysis on the TIMER website revealed that PIK3R1 was highly expressed in almost all the tumors (Figure 9(b)). 10 genes were found to be closely related to PIK3R1 by protein interaction analysis through the STRING website, AKT1, PTEN, ERBB2, PIK3CD, PIK3CA, EGFR, CBL, PIK3CB, IRS1, and SHC1 (Figure 9(c)). KEGG analysis of PIK3R1 showed that the pathway was mainly enriched in the EGF-receptor signaling pathway, insulin/IGF pathway-protein kinase B signaling cascade, p53 pathway, and p53 pathway feedback loops 2 (Figure 9(d)). The mutations and mutation rates of the 11 genes included PIK3R1 that were obtained by the cBioPortal TCGA online analysis tool, and each gene is mutated (Figure 9(e)). Analysis of 10 gene-related pathway network was performed, with white representing tumor-targeted drugs and yellow representing oncology drugs approved by the FDA (Figure 9(f)). We next analyzed the correlation between PIK3R1 and seven genes associated with targeted




FIGURE 5: Determining the hub genes. (a) PPI network of 312 promising target genes in lung adenocarcinoma based on the string website. (b–e) Find hub genes with the CytoHubba plugin in Cytoscape software. Four different metrics were used: DEGREE, MNC, closeness, and betweenness. (f) A Venn diagram used to identify 14 hub genes in lung adenocarcinoma.

drugs. We found that PIK3R1 has strong coexpression relationship with PIK3CB, CBL, EGFR, PIK3CA, PTEN, and PIK3CD, while it has negative relationship with SHC1 (Figure 9(g)).

**3.7. The Biological Role of SPP1 in Tumors.** The difference expression of SPP1 in lung adenocarcinoma and normal tissues was analyzed by the HPA online tool. Surprisingly, SPP1 was highly expressed in lung adenocarcinoma compared to the normal lung tissue (Figure 10(a)). The expression of SPP1 in different tumors and normal tissues by PAN cancer analysis on the TIMER website revealed that SPP1 is highly expressed in almost all tumors (Figure 10(b)). The methylation level of SPP1 in lung adenocarcinoma is significantly decreased (Figure 10(c)) which is determined by the UALCAN online tool. SPP1 is also associated with clinical lymph node metastasis. The SPP1 is most expressed in grade N3 lymph node metastasis compared to N0, N1, and N2 (Figure 10(d)). 10 genes closely related to SPP1 are found by SPP1 protein interaction analysis through the STRING website (Figure 10(e)). KEGG analysis of SPP1 revealed that 10 genes were closely related to it and these genes were mainly enriched in the ECM-receptor interaction pathway (Figure 10(f)). The mutations and mutation rates of these 11 genes that included SPP1 were obtained by the *cBioPortal* TCGA online analysis tool, and each gene is mutated (Figure 10(g)). Analysis of 11 gene-related pathways network was performed, with white representing tumor-targeted drugs and yellow representing oncology drugs approved by the FDA (Figure 10(h)). The relationship between these genes and SPP1 was also analyzed. We found that SPP1 has strong coexpression relationship with TIMP1, FAM20C, IL6, ITGAV, MMP3, FN1, and CD44 (Figure 10(i)).

**3.8. SPP1 Acts as Immune-Related Genes in Lung Adenocarcinoma.** In order to explore the relationship between lung adenocarcinoma and tumor immunity, we analyzed the immune cell infiltration and found that SPP1 is expressed in many immune cells, such as macrophages, and the association of neutrophils and dendritic cells in lung adenocarcinoma with SPP1 was analyzed using the GEPIA website (Figure 11(a))  $P < 0.05$ , while SPP1 was involved in the infiltration of CD4<sup>+</sup> T cells, macrophage and dendritic cells through the TIMER website (Figure 11(b)),  $P < 0.05$ . As immunotherapy is currently mainly focused on immune checkpoint inhibitors, such as CD274, PDCD1, PDCD1LG2, and CTLA4, we further analyzed the coexpression relationship of SPP1 and immune checkpoint-related genes. We are surprised to find that SPP1 has significant coexpression relationship with CD274 and PDCD1LG2 (Figures 11(c) and 11(d)).

## 4. Discussion

Lung cancer is one of the most common malignant tumors in the world, so it poses a serious threat to human health. Worldwide, lung cancer accounts for about 17% of all new

cases of malignant tumors and about 23% of all patients with tumor-related death [26]. Its incidence and mortality are increasing year by year, ranking the first among malignant tumors [27, 28]. Finding out the molecular mechanism and biomarkers related to the occurrence and development of lung cancer has always been the focus and difficulty of clinical and scientific research, which has important research value in improving the diagnosis, treatment efficacy, and prognosis survival of lung cancer patients.

The aim of the present study is through the bioinformatics analysis which is performed systematically to clarify the key effect of the candidate genes and pathways in NSCLC. Gene expression data (expression profiles GSE118370 and GSE10072) were gained from the Gene Expression Omnibus database.

Subsequently, 1,635 and 633 potential DEGs were obtained and identified 88 up-regulated genes and 234 down-regulated genes overlapped in the two GSE datasets in lung adenocarcinoma. Then, we performed enrichment analyses of GO analysis (three methods: CC, MF, and BP), biological pathway, site of expression pathway, KEGG, PANTHER, and REACTOM to analyze up-regulated and down-regulated genes.

The results indicated that the main changes of DEGs in CC are mainly in the extracellular part, and the main differentiation of DEGs in MF is cell adhesion activity, and the main discrepancy of DEGs in the BP is being extraordinarily enriched in cell communication. The epithelial-to-mesenchymal transition had the highest enrichment score in the biological pathway, while the cerebrospinal parts and lungs had the highest enrichment score in the site of the expression pathway. The complement and coagulation cascades had the highest enrichment score in KEGG pathway analysis, and the integrin signaling pathway had the highest enrichment score in the PANTHER pathway analysis, and the extracellular matrix organization had the highest enrichment score in REACTOME pathway analysis.

Furthermore, we constructed a PPI network to analyze the interactional relationships between the DGEs which included 94 nodes and 224 edges. 14 hub genes were identified with three up-regulated genes (CDH1, EPCAM, and SPP1) and ten down-regulated genes (A2M, ACE, ANGPT1, CAV1, CDH5, CLU, CTGF, PECAM1, PIK3R1, and VWF), and one gene had no significance. Surprisingly, the survival analysis revealed that three genes (PIK3R1, SPP1, and PECAM1) have a clear correlation with OS in lung adenocarcinoma patients. Among these three genes, SPP1 is highly expressed in lung adenocarcinoma compared with normal lung tissue, and the high expression is associated with poor prognosis; however, the poor prognosis was associated with the low expression of PECAM1 and PIK3R1. Therefore, we chose these three genes (PIK3R1, SPP1, and PECAM1) as target genes for the next analysis. These three genes have a clear correlation with OS in lung adenocarcinoma patients. SPP1 is highly expressed in lung adenocarcinoma compared with normal lung tissue, and the high expression of SPP1 is associated with poor prognosis, while the high expression of PECAM1 and PIK3R1 is associated with good prognosis. The results indicated that SPP1 is






FIGURE 6: Expression analysis of 13 hub genes in lung adenocarcinoma based on GEPIA. (a) CDH1, (b) EPCAM, (c) SPP1, (d) A2M, (e) ACE, (f) ANGPTL1, (g) CAV1, (h) CDH5, (i) CLU, (j) CTGF, (k) PECAM1, (l) PIK3R1, and (m) VWF;  $P < 0.05$  was considered as statistically significant.

a cancer promoter (oncogene), while PECAM1 and PIK3R1 are cancer suppressor genes.

The oncoming analysis was performed with the survival curves of upstream miRNAs with three genes (PIK3R1, SPP1, and PECAM1), respectively. The results showed that the higher expression of miR-146a-5p on upstream of SPP1 is associated with a higher surviving rate in cancer patients (Figure 8(d)). On the contrary, lower miR-21-5p on upstream of PIK3R1 is associated with a higher surviving rate in cancer patients (Figure 8(e)),  $P < 0.05$ .

Platelet adhesion molecule-1 (PECAM1), a cell adhesion and signaling receptor, is located on chromosome 17q23.3 and encodes a protein found on the surface of monocytes, platelets, neutrophils, and certain types of T cells and makes up most of the intercellular junctions in endothelial cells.

PECAM1 is a member of the immunoglobulin superfamily and is expressed in monocytes, neutrophils, macrophages, and other types of immune cells, as well as endothelial cells [29]. They may be involved in leukocyte migration, angiogenesis, and integrin activation. It was previously reported that PECAM-1 is also associated with advanced metastatic tumor progression [30]. Anti-PECAM-1 antibodies have been reported to inhibit late metastatic progression of various tumors without blocking tumor-platelet and tumor-endothelial interactions, events associated with the initial establishment of metastatic tumor foci. Studies of the molecular mechanism of PECAM-1 have shown that PECAM-1 mediates the release of soluble mediators that stimulate in vitro tumor cell proliferation [31]. Yu et al. determined that PECAM-1 plays a key role in tumorigenesis of LUAD by




FIGURE 7: (a) Survival analysis of 14 hub genes in lung adenocarcinoma based on GEPIA. (b-d) We found that three genes (PECAM1, PIK3R1, and SPP1) were significantly correlated with overall survival.  $P < 0.05$  was considered as statistically significant.

regulating vascular endothelial growth factor (VEGF) expression [32]. In this study, based on the survival and the hub gene analysis, we found that PECAM-1 expression was low in lung adenocarcinoma tissues, and importantly, PECAM-1 expression was associated with worse prognosis in lung adenocarcinoma. It may be an important predictor of prognosis.

Secretory phosphoprotein 1(SPP1) is a secretory acidic glycoprotein with multiple functions, also known as

osteopontin (OPN). It contains the plant homeodomain (PHD) finger, which is a reading domain that typically binds unmethylated H3K4(H3K4me0), dimethylated H3K4(H3K4me2), or trimethylated H3K4(H3K4me3) [33]. It has been reported that it is a key extracellular matrix protein involved in tumor progression and metastasis and is considered as a promising biomarker for prognosis and therapeutic targets [34, 35]. However, it played different functions when in different cell locations. Patients with




FIGURE 8: Upstream miRNA prediction and survival analysis of the three genes were conducted with the miRtarbase. (a) SPP1. (b) PIK3R1. (c) PECAM1. (d, e) miRNA survival analysis used the OncoLnc website, and hsa-miR-146a-5p and hsa-miR-21-5p were significantly correlated with overall survival adenocarcinoma.







FIGURE 9: The biological role of PIK3R1 in tumors. (a) Immunohistochemical analysis of normal lung tissues and lung adenocarcinoma with the HPA online tool, and PIK3R1 was found to be expressed lower in LUAD tissues. (b) Expression of PIK3R1 in various tumors. (c) Interacting proteins for PIK3R1 gene STRING interaction network preview (showing top 10 STRING interactants). (d) Bubble diagram of the PANTHER pathway of PIK3R1 gene. Significant pathways with P value < 0.05 and top 24 were plotted by R language. (e) Variation of PIK3R1 related genes in lung adenocarcinoma. (f) Analysis of the network of regulatory pathways of the 11 genes. White is for tumortargeted drugs, and yellow is for oncology drugs approved by the FDA. (g) The scatter plot showed the correlation between PIK3R1 expression and 7 hub gene signature.




(a)




(b)




(c)




(d)




(e)



(f)



(g)



(h)

FIGURE 10: Continued.




FIGURE 10: The biological role of SPP1 in tumors. (a) Immunohistochemical analysis of normal lung tissues and lung adenocarcinoma with the HPA online tool, and SPP1 was found to be highly expressed in LUAD tissues. (b) Expression of SPP1 in various tumors. (c) The methylation level of SPP1 in normal lung tissues and lung adenocarcinoma. (d) Expression of SPP1 in lung adenocarcinoma based on nodal metastasis status. (e) Interacting proteins for SPP1 gene STRING interaction network preview (showing top 10 STRING interactants). (f) Beautify the results of KEGG pathway analysis with the CLUGO plugin in Cytoscape software. (g) Variation of SPP1 related genes in the lungs. (h) Analysis of the network of regulatory pathways of the 11 genes. The white is for tumor-targeted drugs, and yellow is for oncology drugs approved by the FDA. (i) The scatter plot showed the correlation between the SPP1 expression and the 7 hub gene signature. \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$ .

higher cytoplasmic SPP1 expression levels had a significantly better prognosis than those with lower SPP1 levels. However, when expressed in the nucleus, SPP1 did not show prognostic value in colorectal cancer [36].

This implies that SPP1 overexpression in the cytoplasm is an important and good prognostic biomarker. SPP1 enhances the drug resistance of the second generation EGFR TKI in lung cancer treatment. Inhibition of SPP1 may be a therapeutic target to overcome afatinib resistance [37]. At the same time, studies have found that SPP1 can regulate the expression of PD-L1 to mediate the immune escape of lung adenocarcinoma cells. In addition, SPP1 is also considered a marker of early lymphatic metastasis in lung cancer [38, 39]. This indicates that SPP1 plays an extremely important role in the progression of lung cancer and also provides strong supporting evidence for our findings.

Silencing SPP1 can inhibit the proliferation, invasion, migration, and the EMT process of gastric cancer cells by inhibiting the PI3K/AKT signaling pathway and promote the apoptosis of gastric cancer cells [40]. SPP1 mediates chemotherapy resistance in prostate cancer [41]. In addition, some scholars have demonstrated that inhibition of SPP1 expression can inhibit the progression of melanoma [42]. These evidences suggest that SPP1 plays a role in promoting the progression of various cancers. Therefore, we analyzed the expression of SPP1 in lung cancer and different cancers.

To investigate the relationship between SPP1 and lung adenocarcinoma, we performed immunohistochemistry by using the HPA online tool. It was found that SPP1 was highly expressed in lung adenocarcinoma compared with normal lung tissue. The results of the TIMER website analysis showed that SPP1 was highly expressed in almost all cancers. The methylation level of SPP1 is significantly decreased in lung adenocarcinoma, and SPP1 is clearly associated with clinical lymph node metastasis. We were surprised to find that the expression of SPP1 was associated with miR-146a-5p and the high expression of miR-146a-5p was related to good prognosis.

MicroRNAs (miRNAs) were named as a rank of small noncoding RNA molecules which are less than 22 nucleotides and induce post-transcriptional mRNA degradation after binding to the 3'-untranslated regions (3'UTRs) in target mRNAs [43]. The expression level and regulatory mechanism of miR-146a-5p was diversity and have been reported in a variety of tumors. miR-146a-5p is lowly expressed in lung cancer, gastric cancer, and breast cancer [44–46], and the high expression of exogenous miR-146a-5p can inhibit the proliferation of tumor cells. However, this is in contrast to the high expression level of miR-146a-5p in melanoma and thyroid carcinoma [47, 48]. MiR-146a-5p was a powerful inhibitor in cervical cancer and epithelial ovarian cancer with a better prognosis for patients [49, 50]. This is consistent with our finding that Mir-146A-5p expression is indeed associated with lung adenocarcinoma. In addition, miR-146a-5p has good clinical application value, and the serum level of miR-146a-5p in patients with non-small cell lung cancer is lower, and the expression level indicates a poor prognosis [51]. MiR-146a-5p can also be used as a diagnostic indicator of non-small cell lung cancer [52].

PIK3R1 gene is the regulatory subunit coding gene of PI3K. An increasing number of PIK3R1 has been identified as differentially expressed in many human cancers and associated with tumor progression and metastasis [53]. PIK3R1 is abnormally expressed in a variety of tumors and is associated with increased cell proliferation and invasion. The mutation of PIK3R1 gene in breast cancer, endometrial cancer, and urothelial carcinoma can lead to pathogenesis [54–56]. However, in different types of cancers, it functions differently. In ovarian cancer and colon cancer, PIK3R1 gene played a role of an oncogene [57], while in hepatocellular carcinoma and breast cancer, it played as a tumor suppressor gene [58, 59]. When down-regulated expression of PIK3R1 gene can inhibit PTEN function and reduce the degradation of PIP3 molecule, which was activated PI3K/AKT signaling to play the role of the tumor suppressor gene [60]. The change of the PI3K/AKT




FIGURE 11: Immune correlation analysis in lung adenocarcinoma based on the TIMER website. (a) Relationship between SPP1 and immune cells. (b) The expression of immune cells in lung adenocarcinoma (LUAD). (c) Relationship between SPP1 and CD274 checkpoints. (d) Relationship between SPP1 and PDCD1LG2 checkpoints.

signaling pathway is also related to the occurrence of breast cancer [61]. Studies have found that Mir-21 targeting PIK3R1 can inhibit the migration and invasion of tumor cells by reducing the PI3K/AKT signaling pathway and reversing EMT in breast cancer patients [62]. Although we identified the role of PIK3R1 in exacerbating NSCLC progression, the underlying mechanisms driving tumor progression need to be further elaborated. We therefore analyzed the biological processes in which it might participate. We also found in lung adenocarcinoma that the overexpression of PIK3R1 was associated with miR-21-5p and the low expression of miR-21-5p means good prognosis.

MiR-21-5p is the one unstable strand chain form from mature miR-21 while the other miR-21-3p chain is degraded. MiR-21 was considered an onco-miRNA which participated in oncogenesis via the regulation of a lot of tumor suppressors [63]. The study found that the expression level of Mir-21 in colorectal cancer tissues is higher than that in adjacent tissues, and miR-21-5p promoted proliferation and invasion in colon adenocarcinoma cells [64, 65]. MiR-21-5p induces cell proliferation by targeting TGFBI in non-small cell lung cancer cells [66]. It can inhibit the sensitivity of hepatocellular carcinoma cells to cisplatin [67]. MiR-21-5p has also been reported to be involved in a variety of signaling pathways. It promotes the progression of lung

adenocarcinoma by targeting the SET/TAF-1 $\alpha$  fraction [68]. It also reported MiR-21-5p promoted the occurrence of lung cancer by inhibiting the RAS/MEK/ERK pathway and inhibiting apoptosis [69]. Downregulation of miR-21-5p inhibited both proliferation and apoptosis in oesophageal squamous cell carcinoma cells via the CADM2/Akt pathway [70]. It promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2, and the mechanistic revealed that miR-21 targeted MAPK/ERK and PI3K/AKT signaling pathways to modulate cell proliferation [71]. In our study, we found that PIK3R1 was highly correlated with miR-21-5p and affected the prognosis of patients. Therefore, we believe that PIK3R1 may be regulated by miR-21-5p and participate in the malignant progression of non-small-cell lung cancer.

In our study, we found that SPP1 acted as an immune-related gene. We used the TIMER website to analyze the involvement of the infiltration of macrophages, neutrophils, and dendritic cells. The expression of immune cells was involved in the infiltration of CD4<sup>+</sup> T cells, macrophages, and dendritic cells in lung adenocarcinoma (LUAD). Then, we further analyzed the coexpression of the relationship between SPP1 and immune checkpoint related genes. It was found that SPP1 has significant coexpression relationship with CD274(PD-L1) and PDCD1LG2(PD-1). The immune treatment with (PD-1/PD-L1) is a hot topic in recent years, and the therapeutic effect is encouraging. Studies have shown that PD-L1 was highly expressed in ovarian cancer, melanoma, non-small-cell lung cancer, renal cell cancer, and other tumors, and the expression of PD-1 in CD8<sup>+</sup>T cells infiltrated in tumor sites is higher than that in peripheral blood [72–75]. The combination of PD-L1 and PD-1 inhibited glycolysis, amino acid metabolism, and mitochondrial metabolism. In addition, it can promote the accumulation of polyunsaturated fat A(PUFA) and the oxidation and activation of fatty acids and finally change the metabolic mode of T cells [76, 77].

PD-1 was named the programmed death receptor because of its participation in apoptosis [78]. It is mainly expressed on the surface of T cells, B cells, and natural killer cells. Pd-1 consists of 288 amino acid residues and belongs to the CD28 family, which is located on the PDCD1 gene. Pd-11, also known as CD274, is the major ligand of PD-1 (the other ligand is PD-L2), a 290-amino acid residue transmembrane protein that is mainly expressed in mature immune cells, such as CD4<sup>+</sup>T cells, CD8<sup>+</sup>T cells, B cells, macrophages, dendritic cells, endothelial cells, and other nonimmune cells [79]. These suggested that the PD-1/PD-L1 pathway was abnormally activated in tumors. Studies have shown that the PD-L1 expression in lung adenocarcinoma is associated with many genes and activates multiple pathways. KRAS up-regulated PD-L1 through p-REK instead of the p-AKT pathway, and the PD-1 blocker or ERK inhibitor can rescue the antitumor function of T cells and reduce the survival rate of KRAS mutated non-small-cell lung cancer cells [80]. The expression of PD-L1 can be down-regulated by the EGFR inhibitor erlotinib in lung cancer with EGFR receptor mutation [81]. The patients with positive PD-L1 were also

more sensitive to EGFR tyrosine kinase inhibitors [82]. Studies have shown that chemotherapy, radiotherapy, the cytotoxic T-lymphocyte associated antigen 4 blocker (CTLA4), and other therapeutic methods which produce infiltrating T cells can up-regulate PD-L1 expression through IFN $\gamma$  produced by T cells, which is related to the STAT pathway [83–85].

## 5. Conclusions

This study aims to develop promising novel biomarkers from a new perspective for NSCLC diagnosis, prognosis, and molecular target therapy or immunotherapy. We reveal two potential biomarkers for lung adenocarcinoma, including PIK3R1 and SPP1. Apart from two microRNA, miR-21-5p and miR-146a-5p are related to the prognosis of lung adenocarcinoma which are consistent to PIK3R1 and SPP1. All of these genes take part in the regulation of biological activities in lung adenocarcinoma, providing a basis for improving detection and immunotherapeutic targets for lung adenocarcinoma. Finally, we found that the immune checkpoint-related genes CD274(PD-L1) and PDCD1LG2(PD-1) was related to SPP1 in lung adenocarcinoma. With the development of tumor immunology, tumor immunotherapy is expected to become the successor to surgery, chemotherapy, radiotherapy, and targeted therapy. The previous results also lay a very solid foundation for our nature research and clinical application. However, this study has some limitations, lack of in vivo and in vitro experimental verification. In the future work, we will be trying to study the further mechanisms in the base of bioinformatics.

## Data Availability

All data generated or analyzed during this study are included within this article.

## Consent

The authors have obtained consent to publish this paper from all the participants of this study.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## Authors' Contributions

Junxiu Sheng and Bing Sun designed the research process. Liyan Yu and Xuemei Liang reanalyzed the data and interpreted the results. Jianwei Wang, Guangxiang Ding, Jinhai Tang, and Juan Xue performed the bioinformatics data. Xin He, Jingxuan Ge, Xianzhang Jin, Zhiyi Yang, Hehuan Yao, Hongtao Yin, Wu Liu, shengchen Yin, and Xianwei Li obtained the datasets. Liyan Yu and Xuemei Liang made preliminary revisions to the manuscript, and Sheng Junxiu and Sun Bing made final revisions. All authors reviewed and approved the final manuscript. Bing Sun and Junxiu Sheng contributed equally to this work. Authorship



note: Liyan Yu and Xuemei Liang are contributed equally to this work.

## Acknowledgments

This work was supported by the Natural Science Foundation of China (8212111143) and Natural Science Foundation of Liaoning Province (2020-MS-267).

## Supplementary Materials

Since the picture contains a lot of content. It may be difficult to see clearly because the legend is too small in the reading process. So, we provide the original data of the picture separately. (*Supplementary Materials*)

## References

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: A Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.
- [2] S. V. Ulahannan and J. R. Brahmer, "Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer," *Cancer Investigation*, vol. 29, no. 4, pp. 325–337, 2011.
- [3] V. Boolell, M. Alamgeer, D. N. Watkins, and V. Ganju, "The evolution of therapies in non-small cell lung cancer," *Cancers*, vol. 7, no. 3, pp. 1815–1846, 2015.
- [4] A. Khakwani, A. L. Rich, H. A. Powell et al., "Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit," *British Journal of Cancer*, vol. 109, no. 8, pp. 2058–2065, 2013.
- [5] S. I. Rothschild, "Advanced and metastatic lung cancer – what is new in the diagnosis and therapy?" *Praxis*, vol. 104, no. 14, pp. 745–750, 2015.
- [6] W. Song, Z. Tang, M. Li et al., "Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects," *Acta Biomaterialia*, vol. 10, no. 3, pp. 1392–1402, 2014.
- [7] A. Sibille, A. Paulus, M. Martin et al., "Management of non-small cell lung cancer," *Revue Medicale de Liege*, vol. 70, no. 9, pp. 432–441, 2015.
- [8] X. Lu, D. Zhou, B. Hou et al., "Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer," *Cancer Management and Research*, vol. 10, pp. 1231–1241, 2018.
- [9] Y. L. Wu and F. Y. Niu, "Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib," *OncoTargets and Therapy*, vol. 8, pp. 999–1007, 2015.
- [10] M. Ni, X. Liu, J. Wu et al., "Identification of candidate biomarkers correlated with the pathogenesis and prognosis of non-small cell lung cancer via integrated bioinformatics analysis," *Frontiers in Genetics*, vol. 9, p. 469, 2018.
- [11] T. Barrett, S. E. Wilhite, P. Ledoux et al., "NCBI GEO: archive for functional genomics data sets--update," *Nucleic Acids Research*, vol. 41, no. D1, pp. D991–D995, 2012.
- [12] G. K. Smyth, "Linear models and empirical bayes methods for assessing differential expression in microarray experiments," *Statistical applications in genetics and molecular biology*, vol. 3, 2004.
- [13] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," *Nucleic Acids Research*, vol. 45, no. W1, pp. W98–w102, 2017.
- [14] Y. Liao, J. Wang, E. J. Jaehnig, Z. Shi, and B. Zhang, "WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs," *Nucleic Acids Research*, vol. 47, no. W1, pp. W199–w205, 2019.
- [15] G. Bindea, B. Mlecnik, H. Hackl et al., "ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks," *Bioinformatics*, vol. 25, no. 8, pp. 1091–1093, 2009.
- [16] M. E. Smoot, K. Ono, J. Ruscheinski, P. L. Wang, and T. Ideker, "Cytoscape 2.8: new features for data integration and network visualization," *Bioinformatics*, vol. 27, no. 3, pp. 431–432, 2011.
- [17] H. Mi, X. Huang, A. Muruganujan et al., "PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements," *Nucleic Acids Research*, vol. 45, no. D1, pp. D183–D189, 2017.
- [18] A. Fabregat, K. Sidiropoulos, P. Garapati et al., "The reactome pathway knowledgebase," *Nucleic Acids Research*, vol. 44, no. D1, pp. D481–D487, 2016.
- [19] D. Szklarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," *Nucleic Acids Research*, vol. 47, no. D1, pp. D607–D613, 2019.
- [20] C. H. Chin, S. H. Chen, H. H. Wu, C. W. Ho, M. T. Ko, and C. Y. Lin, "cytoHubba: identifying hub objects and sub-networks from complex interactome," *BMC Systems Biology*, vol. 8, no. 4, p. S11, 2014.
- [21] J. Anaya, "OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs," *PeerJ Computer Science*, vol. 2, p. e67, 2016.
- [22] D. S. Chandrashekar, B. Bashel, S. A. H. Balasubramanya et al., "UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses," *Neoplasia*, vol. 19, no. 8, pp. 649–658, 2017.
- [23] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists," *Nucleic Acids Research*, vol. 37, no. 1, pp. 1–13, 2009.
- [24] M. Uhlén, L. Fagerberg, B. M. Hallström et al., "Proteomics. Tissue-based map of the human proteome," *Science (New York, NY)*, vol. 347, no. 6220, Article ID 1260419, 2015.
- [25] T. Li, J. Fan, B. Wang et al., "TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells," *Cancer Research*, vol. 77, no. 21, pp. e108–e110, 2017.
- [26] J. A. Barta, C. A. Powell, and J. P. Wisnivesky, "Global epidemiology of lung cancer," *Annals of global health*, vol. 85, no. 1, p. 8, 2019.
- [27] K. D. Miller, R. L. Siegel, C. C. Lin et al., "Cancer treatment and survivorship statistics," *CA: A Cancer Journal for Clinicians*, vol. 66, no. 4, pp. 271–289, 2016.
- [28] R. A. Smith, K. S. Andrews, D. Brooks et al., "Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening," *CA: A Cancer Journal for Clinicians*, vol. 68, no. 4, pp. 297–316, 2018.

- [29] S. Micheline, B. Amato, S. Kenanoglu et al., "Rare PECAM1 variants in three families with lymphedema," *Lymphology*, vol. 53, no. 3, pp. 141–151, 2021.
- [30] H. DeLisser, Y. Liu, P. Y. Desprez et al., "Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression," *Proceedings of the National Academy of Sciences*, vol. 107, no. 43, pp. 18616–18621, 2010.
- [31] V. Abraham, G. Cao, A. Parambath et al., "Involvement of TIMP-1 in PECAM-1-mediated tumor dissemination," *International Journal of Oncology*, vol. 53, no. 2, pp. 488–502, 2018.
- [32] D. H. Yu, J. Y. Huang, X. P. Liu et al., "Effects of hub genes on the clinicopathological and prognostic features of lung adenocarcinoma," *Oncology Letters*, vol. 19, no. 2, pp. 1203–1214, 2020.
- [33] C. A. Musselman and T. G. Kutateladze, "The PHD finger of Spp1 mediates histone modification cross-talk," *Biochemical Journal*, vol. 476, no. 16, pp. 2351–2354, 2019.
- [34] L. M. Castello, D. Raineri, L. Salmi et al., "Osteopontin at the crossroads of inflammation and tumor progression," *Mediators of Inflammation*, vol. 2017, pp. 1–22, 2017.
- [35] R. Wei, J. P. C. Wong, and H. F. Kwok, "Osteopontin -- a promising biomarker for cancer therapy," *Journal of Cancer*, vol. 8, no. 12, pp. 2173–2183, 2017.
- [36] M. Assidi, W. Goma, M. Jafri et al., "Prognostic value of Osteopontin (SPP1) in colorectal carcinoma requires a personalized molecular approach," *Tumor Biology*, vol. 41, no. 9, Article ID 101042831986362, 2019.
- [37] X. Wang, F. Zhang, X. Yang et al., "Secreted phosphoprotein 1 (SPP1) contributes to second-generation EGFR tyrosine kinase inhibitor resistance in non-small cell lung cancer," *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, vol. 27, no. 8, pp. 871–877, 2019.
- [38] Y. Zhang, W. Du, Z. Chen, and C. Xiang, "Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma," *Experimental Cell Research*, vol. 359, no. 2, pp. 449–457, 2017.
- [39] B. Dong, C. Wu, L. Huang, and Y. Qi, "Macrophage-related SPP1 as a potential biomarker for early lymph node metastasis in lung adenocarcinoma," *Frontiers in Cell and Developmental Biology*, vol. 9, Article ID 739358, 2021.
- [40] S. Z. Song, S. Lin, J. N. Liu et al., "Retracted: targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway," *Journal of Cellular Physiology*, vol. 234, no. 10, pp. 18587–18601, 2019.
- [41] X. Pang, J. Zhang, X. He et al., "SPP1 promotes enzalutamide resistance and epithelial-mesenchymal-transition activation in castration-resistant prostate cancer via PI3K/AKT and ERK1/2 pathways," *Oxidative Medicine and Cellular Longevity*, vol. 2021, pp. 1–15, 2021.
- [42] T. Kiss, K. Jámor, V. Koroknai et al., "Silencing osteopontin expression inhibits proliferation, invasion and induce altered protein expression in melanoma cells," *Pathology and Oncology Research*, vol. 27, Article ID 581395, 2021.
- [43] M. Chekulaeva and W. Filipowicz, "Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells," *Current Opinion in Cell Biology*, vol. 21, no. 3, pp. 452–460, 2009.
- [44] Y. L. Li, J. Wang, C. Y. Zhang et al., "MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2," *Oncotarget*, vol. 7, no. 37, pp. 59287–59298, 2016.
- [45] Q. Yao, C. Tu, D. Lu, Y. Zou, H. Liu, and S. Zhang, "Clinicopathological significance of the microRNA-146a/WASP-family verprolin-homologous protein-2 axis in gastric cancer," *Cancer Science*, vol. 108, no. 7, pp. 1285–1292, 2017.
- [46] E. Kumaraswamy, K. L. Wendt, L. A. Augustine et al., "BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function," *Oncogene*, vol. 34, no. 33, pp. 4333–4346, 2015.
- [47] D. Philippidou, M. Schmitt, D. Moser et al., "Signatures of microRNAs and selected microRNA target genes in human melanoma," *Cancer Research*, vol. 70, no. 10, pp. 4163–4173, 2010.
- [48] M. Sun, S. Fang, W. Li et al., "Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma," *Cancer Biomarkers*, vol. 15, no. 1, pp. 33–40, 2015.
- [49] E. Peta, A. Sinigaglia, G. Masi et al., "HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axis," *Oncogene*, vol. 37, no. 12, pp. 1654–1668, 2018.
- [50] M. Wilczyński, E. Żyto, B. Szymańska et al., "Expression of miR-146a in patients with ovarian cancer and its clinical significance," *Oncology Letters*, vol. 14, no. 3, pp. 3207–3214, 2017.
- [51] C. Wu, Y. Cao, Z. He et al., "Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer," *Tohoku Journal of Experimental Medicine*, vol. 232, no. 2, pp. 85–95, 2014.
- [52] R. J. Wang, Y. H. Zheng, P. Wang, and J. Z. Zhang, "Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 1, pp. 765–771, 2015.
- [53] Y. Lin, Z. Yang, A. Xu et al., "PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3 $\beta$ /CTNBN1 signaling pathway," *Scientific Reports*, vol. 5, no. 1, p. 8997, 2015.
- [54] T. W. Miller, B. N. Rexer, J. T. Garrett, and C. L. Arteaga, "Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer," *Breast Cancer Research*, vol. 13, no. 6, p. 224, 2011.
- [55] M. E. Urick, M. L. Rudd, A. K. Godwin, D. Sgroi, M. Merino, and D. W. Bell, "PIK3R1 (p85 $\alpha$ ) is somatically mutated at high frequency in primary endometrial cancer," *Cancer Research*, vol. 71, no. 12, pp. 4061–4067, 2011.
- [56] G. Sjö Dahl, M. Lauss, S. Gudjonsson et al., "A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1," *PLoS One*, vol. 6, no. 4, Article ID e18583, 2011.
- [57] A. J. Philp, I. G. Campbell, C. Leet et al., "The phosphatidylinositol 3'-kinase p85 $\alpha$  gene is an oncogene in human ovarian and colon tumors," *Cancer Research*, vol. 61, no. 20, pp. 7426–7429, 2001.
- [58] X. P. Huang, J. Hou, X. Y. Shen et al., "MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1," *FEBS Journal*, vol. 282, no. 3, pp. 579–594, 2015.
- [59] M. Cizkova, S. Vacher, D. Meseure et al., "PIK3R1 under-expression is an independent prognostic marker in breast cancer," *BMC Cancer*, vol. 13, no. 1, p. 545, 2013.
- [60] C. M. Taniguchi, J. Winnay, T. Kondo et al., "The phosphoinositide 3-kinase regulatory subunit p85 $\alpha$  can exert

- tumor suppressor properties through negative regulation of growth factor signaling," *Cancer Research*, vol. 70, no. 13, pp. 5305–5315, 2010.
- [61] S. L. Moulder, "Does the PI3K pathway play a role in basal breast cancer?" *Clinical Breast Cancer*, vol. 10, no. 13, pp. S66–S71, 2010.
- [62] L. X. Yan, Y. H. Liu, J. W. Xiang et al., "PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer," *International Journal of Oncology*, vol. 48, no. 2, pp. 471–484, 2016.
- [63] S. R. Pfeffer, C. H. Yang, and L. M. Pfeffer, "The role of miR-21 in cancer," *Drug Development Research*, vol. 76, no. 6, pp. 270–277, 2015.
- [64] A. Ferraro, C. K. Kontos, T. Boni et al., "Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB4-PDCD4) as predictor of metastatic tumor potential," *Epigenetics*, vol. 9, no. 1, pp. 129–141, 2014.
- [65] W. Yu, K. Zhu, Y. Wang, H. Yu, and J. Guo, "Overexpression of miR-21-5p promotes proliferation and invasion of colon adenocarcinoma cells through targeting CHL1," *Molecular Medicine*, vol. 24, no. 1, p. 36, 2018.
- [66] L. Yan, J. Ma, Y. Wang et al., "miR-21-5p induces cell proliferation by targeting TGFBI in non-small cell lung cancer cells," *Experimental and Therapeutic Medicine*, vol. 16, no. 6, pp. 4655–4663, 2018.
- [67] S. Chen, C. Yang, C. Sun et al., "miR-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG," *DNA and Cell Biology*, vol. 38, no. 8, pp. 865–873, 2019.
- [68] J. Zhong, X. Ren, Z. Chen et al., "miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-1a," *Life Sciences*, vol. 231, Article ID 116539, 2019.
- [69] M. E. Hatley, D. M. Patrick, M. R. Garcia et al., "Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21," *Cancer Cell*, vol. 18, no. 3, pp. 282–293, 2010.
- [70] X. Li, D. Chen, M. Li, X. Gao, G. Shi, and H. Zhao, "The CADM2/Akt pathway is involved in the inhibitory effect of miR-21-5p downregulation on proliferation and apoptosis in esophageal squamous cell carcinoma cells," *Chemico-Biological Interactions*, vol. 288, pp. 76–82, 2018.
- [71] Q. Zhao, S. Chen, Z. Zhu et al., "miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2," *Cell Death & Disease*, vol. 9, no. 12, p. 1157, 2018.
- [72] K. Abiko, N. Matsumura, J. Hamaishi et al., "IFN- $\gamma$  from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer," *British Journal of Cancer*, vol. 112, no. 9, pp. 1501–1509, 2015.
- [73] V. Audrito, S. Serra, A. Stingi et al., "PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p," *Oncotarget*, vol. 8, no. 9, pp. 15894–15911, 2017.
- [74] K. J. Lastwika, W. Wilson 3rd, Q. K. Li et al., "Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer," *Cancer Research*, vol. 76, no. 2, pp. 227–238, 2016.
- [75] M. Ruf, H. Moch, and P. Schraml, "PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma," *International Journal of Cancer*, vol. 139, no. 2, pp. 396–403, 2016.
- [76] A. Jaudszus, M. Gruen, B. Watzl et al., "Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells," *The Journal of Lipid Research*, vol. 54, no. 4, pp. 923–935, 2013.
- [77] N. Patsoukis, K. Bardhan, P. Chatterjee et al., "PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation," *Nature Communications*, vol. 6, no. 1, p. 6692, 2015.
- [78] Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death," *The EMBO Journal*, vol. 11, no. 11, pp. 3887–3895, 1992.
- [79] J. Chen, C. C. Jiang, L. Jin, and X. D. Zhang, "Regulation of PD-L1: a novel role of pro-survival signalling in cancer," *Annals of Oncology*, vol. 27, no. 3, pp. 409–416, 2016.
- [80] N. Chen, W. Fang, Z. Lin et al., "KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma," *Cancer Immunology, Immunotherapy*, vol. 66, no. 9, pp. 1175–1187, 2017.
- [81] B. P. Pollack, "EGFR inhibitors, MHC expression and immune responses: can EGFR inhibitors be used as immune response modifiers?" *Onc Immunology*, vol. 1, no. 1, pp. 71–74, 2012.
- [82] Z. Gatalica, C. Snyder, T. Maney et al., "Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research," *cosponsored by the Cancer Epidemiology, Biomarkers & Prevention*, vol. 23, no. 12, pp. 2965–2970, 2014.
- [83] D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy," *Nature Reviews Cancer*, vol. 12, no. 4, pp. 252–264, 2012.
- [84] L. Deng, H. Liang, B. Burnette et al., "Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice," *Journal of Clinical Investigation*, vol. 124, no. 2, pp. 687–695, 2014.
- [85] R. Das, R. Verma, M. Sznol et al., "Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo," *The Journal of Immunology (Baltimore, Md: 1950)*, vol. 194, no. 3, pp. 950–959, 2015.